ATLANTA--(BUSINESS WIRE)--Better Walk, an Atlanta-based medical device company, closed a Series A round of $450,000 this past week. This is the company's third round of funding to date, bringing the total funding raised to $600,000.
The round was led by MB Venture Partners, a Memphis-based venture capital firm. Gary Stevenson, co-founder and Managing Partner, will join the Better Walk board of directors.
"The funding will help us to continue down the path of manufacturing and distributing the Better Walk Crutch to patients who need it," said Partha Unnava, CEO of Better Walk.
The Better Walk Crutch was created after Partha Unnava broke his ankle, spent time on crutches, and experienced the pain suffered by so many crutch users firsthand. The Better Walk crutch is an alternative to traditional underarm or forearm crutches that removes force from the user's underarm area and distributes it along the user’s body. Since founding, the company has focused on developing the product and is gearing up for a launch this spring.
About Better Walk
Better Walk was founded in May 2013 by three Georgia Tech biomedical engineering students and was selected as one of six companies to participate in the 2013 Zero To 510 medical device accelerator in Memphis, TN. Better Walk is developing a new type of crutch that improves the experience of a crutch user. Better Walk was selected as one of the top companies in the Zero To 510 accelerator class of 2013. Additionally, Better Walk has also presented at the White House to President Barack Obama, at the Georgia Bio Shark Tank 2013, SEMDA 2014, and AAOS 2014.
For more information on Better Walk, please visit www.bwcrutches.com, or contact Partha Unnava at partha@bwcrutches.com. Press kit here: https://www.dropbox.com/sh/zgpcw94th5hetyx/AAAe7SxoriualxTDSH_1uOPva?dl=0.
About MB Venture Partners
MB Venture Partners is a Memphis-based venture capital firm that provides venture capital and strategic direction to life sciences companies. The firm invests in medical device and biotech companies at various stages of development and is especially interested in product solutions for musculoskeletal disease. The firm manages funds totaling more than $120 million in committed capital and has invested in nearly 40 start-ups. Visit www.mbventures.com for more information.
